$FHTX
Foghorn Therapeutics Inc.

2024 Q3 Form 10-Q Financial Statement

#000162828024035867 Filed on August 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $7.808M $6.888M
YoY Change -55.33% 23.02%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.971M $7.325M
YoY Change -16.11% -12.81%
% of Gross Profit
Research & Development $24.69M $23.80M
YoY Change -5.95% -18.64%
% of Gross Profit
Depreciation & Amortization $700.0K $800.0K
YoY Change -22.22% -8.68%
% of Gross Profit
Operating Expenses $31.66M $33.52M
YoY Change -8.39% -10.97%
Operating Profit -$23.85M -$26.63M
YoY Change 39.64% -16.9%
Interest Expense $3.495M $2.870M
YoY Change 27.09% 2.76%
% of Operating Profit
Other Income/Expense, Net $4.730M $3.653M
YoY Change 36.15% 413.06%
Pretax Income -$19.12M -$22.98M
YoY Change 40.53% -19.5%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$19.12M -$22.98M
YoY Change 33.3% -22.07%
Net Earnings / Revenue -244.9% -333.61%
Basic Earnings Per Share -$0.31 -$0.45
Diluted Earnings Per Share -$0.31 -$0.45
COMMON SHARES
Basic Shares Outstanding 55.33M shares 42.59M shares
Diluted Shares Outstanding 62.60M shares 51.58M shares

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $267.4M $285.2M
YoY Change 2.89% 0.3%
Cash & Equivalents $57.68M $138.9M
Short-Term Investments $209.7M $146.2M
Other Short-Term Assets $3.837M $4.444M
YoY Change -31.48% -28.1%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $271.2M $289.6M
YoY Change 2.18% -0.3%
LONG-TERM ASSETS
Property, Plant & Equipment $34.58M $36.26M
YoY Change -23.32% -21.53%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $848.0K $1.001M
YoY Change -24.89% -65.26%
Total Long-Term Assets $37.14M $38.96M
YoY Change -22.6% -20.62%
TOTAL ASSETS
Total Short-Term Assets $271.2M $289.6M
Total Long-Term Assets $37.14M $38.96M
Total Assets $308.4M $328.6M
YoY Change -1.61% -3.24%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.451M $4.813M
YoY Change -46.88% -30.58%
Accrued Expenses $11.22M $6.452M
YoY Change 27.5% -58.94%
Deferred Revenue $33.38M $31.23M
YoY Change 17.78% -7.86%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $56.82M $50.87M
YoY Change 9.25% -10.18%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $279.8M $292.0M
YoY Change -12.11%
Total Long-Term Liabilities $279.8M $292.0M
YoY Change -12.11%
TOTAL LIABILITIES
Total Short-Term Liabilities $56.82M $50.87M
Total Long-Term Liabilities $279.8M $292.0M
Total Liabilities $336.7M $342.9M
YoY Change -9.21% -11.83%
SHAREHOLDERS EQUITY
Retained Earnings -$538.7M -$519.6M
YoY Change 20.38% 19.97%
Common Stock $6.000K $6.000K
YoY Change 50.0% 50.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$28.29M -$14.32M
YoY Change
Total Liabilities & Shareholders Equity $308.4M $328.6M
YoY Change -1.61% -3.24%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$19.12M -$22.98M
YoY Change 33.3% -22.07%
Depreciation, Depletion And Amortization $700.0K $800.0K
YoY Change -22.22% -8.68%
Cash From Operating Activities -$21.01M -$25.54M
YoY Change -22.78% -20.63%
INVESTING ACTIVITIES
Capital Expenditures $309.0K $17.00K
YoY Change 209.0% -96.38%
Acquisitions
YoY Change
Other Investing Activities -$61.01M -$17.96M
YoY Change -258.05% -145.35%
Cash From Investing Activities -$61.32M -$17.98M
YoY Change -259.26% -145.93%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.051M 103.2M
YoY Change -24.93% 100100.0%
NET CHANGE
Cash From Operating Activities -21.01M -25.54M
Cash From Investing Activities -61.32M -17.98M
Cash From Financing Activities 1.051M 103.2M
Net Change In Cash -81.27M 59.69M
YoY Change -739.91% 745.28%
FREE CASH FLOW
Cash From Operating Activities -$21.01M -$25.54M
Capital Expenditures $309.0K $17.00K
Free Cash Flow -$21.31M -$25.55M
YoY Change -21.93% -21.72%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
4000 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
505569000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
395196000 usd
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-338000 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-826000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-519559000 usd
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.70
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.70
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.43
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.43
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51580310 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51580310 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41825555 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41825555 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47004561 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47004561 shares
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
0 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3168000 usd
CY2024Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
159000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-22979000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-14322000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
112000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
102000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4572000 usd
CY2023Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
1116000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-30488000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-24586000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
102000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4470000 usd
CY2023Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
151000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-29487000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-49350000 usd
us-gaap Net Income Loss
NetIncomeLoss
-47995000 usd
us-gaap Net Income Loss
NetIncomeLoss
-59975000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
6392000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
9041000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1626000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1735000 usd
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
2398000 usd
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0 usd
fhtx Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
2869000 usd
fhtx Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
2490000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1259000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1501000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1793000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-626000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1458000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1520000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-3112000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2819000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-4197000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-3564000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-11939000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-10908000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-54882000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-63355000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
118000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1105000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
97367000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
63202000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
106605000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
132946000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
9120000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
68639000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
103401000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
195000 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1167000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
205000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
104373000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
205000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
58611000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5489000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
82044000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53922000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
140655000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
59411000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
754000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1690000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
112000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
87000 usd
fhtx Non Cash Offering Cost
NonCashOfferingCost
390000 usd
fhtx Non Cash Offering Cost
NonCashOfferingCost
0 usd
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
138947000 usd
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57703000 usd
CY2024Q2 us-gaap Restricted Cash Equivalents
RestrictedCashEquivalents
1708000 usd
CY2023Q2 us-gaap Restricted Cash Equivalents
RestrictedCashEquivalents
1708000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
140655000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
59411000 usd
us-gaap Net Income Loss
NetIncomeLoss
-48000000 usd
us-gaap Net Income Loss
NetIncomeLoss
-60000000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-519600000 usd
CY2023Q4 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 segment
CY2024Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
146568000 usd
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 usd
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
338000 usd
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
146230000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
154547000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
18000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
844000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
153721000 usd
CY2024Q2 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
24362000 usd
CY2023Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
24973000 usd
CY2024Q2 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
13602000 usd
CY2023Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
12017000 usd
CY2024Q2 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
10760000 usd
CY2023Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
12956000 usd
CY2023Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
800000 usd
CY2024Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
800000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1600000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1700000 usd
CY2024Q2 us-gaap Impairment Of Leasehold
ImpairmentOfLeasehold
800000 usd
us-gaap Impairment Of Leasehold
ImpairmentOfLeasehold
800000 usd
CY2024Q2 fhtx Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
2937000 usd
CY2023Q4 fhtx Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
3646000 usd
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2583000 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4347000 usd
CY2024Q2 us-gaap Accrued Income Taxes
AccruedIncomeTaxes
0 usd
CY2023Q4 us-gaap Accrued Income Taxes
AccruedIncomeTaxes
674000 usd
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
693000 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
441000 usd
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
239000 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
0 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6452000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9108000 usd
CY2024Q2 fhtx Common Stock Voting Rights Votes
CommonStockVotingRightsVotes
1 vote
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
7220794 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
fhtx Class Of Warrant Or Right Pre Funded Warrants Exercised
ClassOfWarrantOrRightPreFundedWarrantsExercised
0 shares
CY2024Q2 fhtx Class Of Warrant Or Right Pre Funded Warrants Exercised
ClassOfWarrantOrRightPreFundedWarrantsExercised
0 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9246327 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9760228 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
1566120 shares
CY2024Q2 us-gaap Share Based Compensation
ShareBasedCompensation
3168000 usd
CY2023Q2 us-gaap Share Based Compensation
ShareBasedCompensation
4470000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
6392000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
9041000 usd
CY2024Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
20600000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y2M12D
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false

Files In Submission

Name View Source Status
0001628280-24-035867-index-headers.html Edgar Link pending
0001628280-24-035867-index.html Edgar Link pending
0001628280-24-035867.txt Edgar Link pending
0001628280-24-035867-xbrl.zip Edgar Link pending
fhtx-20240630.htm Edgar Link pending
fhtx-20240630.xsd Edgar Link pending
fhtx-20240630xex311.htm Edgar Link pending
fhtx-20240630xex312.htm Edgar Link pending
fhtx-20240630xex321.htm Edgar Link pending
fhtx-20240630xex322.htm Edgar Link pending
fhtx-20240630_cal.xml Edgar Link unprocessable
fhtx-20240630_def.xml Edgar Link unprocessable
fhtx-20240630_htm.xml Edgar Link completed
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
fhtx-20240630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
fhtx-20240630_lab.xml Edgar Link unprocessable